APOE4 is a variant of the APOE gene, which provides instructions for making a protein that carries cholesterol and other fats through your bloodstream and brain. Everyone inherits two copies of the APOE gene (one from each parent), and those copies can be any combination of three versions: e2, e3, or e4. The e3 version is the most common. The e4 version is the one linked to a significantly higher risk of Alzheimer’s disease and cardiovascular problems.
Roughly 25% of people carry at least one copy of APOE4, and about 2-3% carry two copies. Having this gene variant doesn’t mean you’ll develop Alzheimer’s, but it shifts the odds in a way worth understanding.
What the APOE Gene Actually Does
The protein made by the APOE gene acts like a delivery vehicle. It attaches to particles of cholesterol and other fats in your blood and guides them to cells that need them, docking at receptors on cell surfaces so the fats can be pulled inside. This process is essential for redistributing lipids throughout the body, including the brain, where cholesterol plays a critical role in maintaining healthy nerve cells.
All three versions of the gene do this job, but they don’t do it identically. APOE4 has a structural quirk that changes which fat particles it prefers to carry. While the e3 and e2 versions tend to attach to smaller, phospholipid-rich HDL particles (the “good cholesterol” carriers), APOE4 preferentially binds to larger, triglyceride-rich VLDL particles. This preference is driven by a specific interaction between two parts of the protein’s structure that fold differently in the e4 version. The practical result is that APOE4 carriers tend to have higher levels of circulating “bad” cholesterol, which has consequences for both the heart and the brain.
APOE4 and Alzheimer’s Risk
APOE4 is the strongest known genetic risk factor for late-onset Alzheimer’s disease. One copy of e4 raises your risk two to three times compared to someone with two copies of the common e3 variant. Two copies of e4 raise the risk roughly tenfold.
A 2025 analysis of approximately 470,000 participants across four large studies found that the combined effect of the e3 and e4 alleles accounts for the vast majority of Alzheimer’s cases. Depending on the dataset, between 72% and 93% of Alzheimer’s cases were attributable to carrying these variants rather than the protective e2/e2 combination. The researchers concluded that without the underlying risk from e3 and e4, almost all Alzheimer’s disease and about half of all dementia cases would not occur.
These are population-level statistics, not personal predictions. Many people with one or even two copies of APOE4 never develop Alzheimer’s. And people with no copies of e4 still can.
How APOE4 Affects the Brain
Alzheimer’s disease is characterized by the buildup of a sticky protein fragment called amyloid-beta in the brain. Normally, brain cells clear this waste efficiently. APOE4 disrupts that cleanup process.
The mechanism is indirect. Rather than binding directly to amyloid-beta in brain fluid, the APOE4 protein competes with amyloid-beta for the same cellular cleanup pathways. Brain support cells called astrocytes use specific receptors to pull in and break down waste proteins. When APOE4 is present, it essentially hogs those receptors, blocking amyloid-beta from being taken up and degraded. In mouse studies, infusing APOE4 particles into the brain increased the level of amyloid-beta floating in brain fluid by about 37% above baseline. Over years, this reduced clearance allows amyloid to accumulate into the plaques associated with Alzheimer’s.
The clearance rate follows a clear hierarchy by gene variant: e4 clears amyloid the slowest, e3 is faster, and e2 is fastest. This gradient maps neatly onto the Alzheimer’s risk associated with each version.
Cardiovascular Effects
The brain risks tend to get the most attention, but APOE4 also raises the risk of cardiovascular disease, including coronary artery disease, heart attack, and both ischemic and hemorrhagic stroke. This is partly because of APOE4’s preference for binding VLDL particles, which promotes higher levels of cholesterol that contributes to plaque buildup in arteries.
There’s also evidence that APOE4 and cardiovascular risk factors work together in a way that’s worse than either alone. High cholesterol is more strongly associated with cognitive decline in APOE4 carriers than in non-carriers, suggesting that vascular damage preferentially accelerates brain pathology when e4 is in the picture. In one study, APOE4 carriers with elevated “bad” cholesterol showed impaired blood flow responses in the brain during exercise, a sign of cerebrovascular dysfunction that wasn’t seen in non-carriers with the same cholesterol levels.
Who Carries APOE4
APOE4 is actually the ancestral version of the gene, meaning it was the original form in early human populations. Its frequency has declined as human diets and lifestyles changed, but it remains more common in populations with historical or recent foraging economies. Among African Pygmy populations, the e4 frequency is around 41%. Among Khoi San populations, it’s 37%. Australian aborigines carry it at about 26%, and Papuan populations at 37%. Among people of European descent, the frequency is lower, typically around 15%.
One hypothesis is that APOE4 was advantageous when food was scarce and sporadically available, helping with efficient fat absorption and energy use. In modern environments with abundant calories, those same properties may contribute to the cardiovascular and neurological risks we see today.
Getting Tested for APOE4
You can find out your APOE status through a simple DNA test, either a blood draw or a cheek swab ordered by a healthcare provider, or through direct-to-consumer genetic testing kits. The test identifies which two copies of the APOE gene you carry.
It’s important to understand what the result does and doesn’t tell you. A positive result for one or two copies of e4 identifies a risk factor. It is not a diagnosis of Alzheimer’s or any other disease. For people already diagnosed with Alzheimer’s, knowing their APOE status can help guide treatment decisions, as some newer therapies have different safety profiles depending on APOE genotype.
Whether to get tested is a personal decision. Some people find the information motivating. Others find it anxiety-inducing, especially given that the result doesn’t change in either direction. Genetic counseling before testing can help you think through what you’d do with the information.
Lifestyle Factors That Matter More for Carriers
The relationship between APOE4 and lifestyle is one of the more encouraging findings in recent research. Certain habits appear to benefit APOE4 carriers even more than non-carriers, meaning the people at highest genetic risk may also have the most to gain from protective behaviors.
A study examining how lifestyle factors interact with APOE4 status found that social engagement and mindfulness practice had a significantly stronger positive effect on cognitive reserve in e4 carriers than in non-carriers. For social engagement specifically, the protective association was statistically meaningful only in carriers, with no measurable effect in non-carriers. The same pattern held for mindfulness. Interestingly, physical activity, the MIND diet, cognitive leisure activities, and education level did not show this same carrier-specific boost, though they remain beneficial for brain health in general.
Managing cardiovascular risk factors may be especially important for APOE4 carriers given the synergistic relationship between e4 and vascular health. Keeping cholesterol in a healthy range, staying physically active, and maintaining good blood pressure all help protect the cerebrovascular system that APOE4 makes more vulnerable.